Biomunex Pharmaceuticals SA, of Paris, said it established a U.S. subsidiary, Biomunex Pharmaceuticals Inc., based in Cambridge, Mass. The company's plug-and-play Bixab platform is designed to generate next-generation bi- and multispecific antibodies.